Viatris Crecimiento futuro

Future controles de criterios 2/6

Se prevé que los ingresos de Viatris disminuyan en un 1.2% al año, mientras que se espera que sus beneficios anuales crezcan en un 16% al año. Se prevé que el BPA crezca en un 20.2% anual. Se prevé que la rentabilidad financiera sea de 11% en 3 años.

Información clave

16.0%

Tasa de crecimiento de los beneficios

20.2%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	23.0%
Tasa de crecimiento de los ingresos	-1.2%
Rentabilidad financiera futura	11.0%
Cobertura de analistas	Good
Última actualización	19 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:VTRS - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	14,974	876	2,489	3,182	6
12/31/2025	14,984	989	2,658	3,185	8
12/31/2024	15,219	1,885	2,475	3,092	8
12/31/2023	15,427	55	2,325	2,800	N/A
9/30/2023	15,466	1,832	2,023	2,463	N/A
6/30/2023	15,602	1,854	2,045	2,498	N/A
3/31/2023	15,800	1,904	2,332	2,785	N/A
12/31/2022	16,263	2,079	2,510	2,953	N/A
9/30/2022	16,728	804	2,835	3,333	N/A
6/30/2022	17,187	761	3,035	3,550	N/A
3/31/2022	17,648	168	2,779	3,307	N/A
12/31/2021	17,886	-1,269	2,508	3,017	N/A
9/30/2021	17,168	-1,921	1,784	2,530	N/A
6/30/2021	15,604	-2,047	1,296	1,969	N/A
3/31/2021	13,757	-1,728	1,166	1,790	N/A
12/31/2020	11,946	-670	551	1,232	N/A
9/30/2020	11,514	266	1,539	1,882	N/A
6/30/2020	11,504	271	1,502	1,845	N/A
3/31/2020	11,624	63	1,687	2,135	N/A
12/31/2019	11,501	17	1,398	1,804	N/A
9/30/2019	11,387	48	1,022	1,753	N/A
6/30/2019	11,288	34	1,187	1,919	N/A
3/31/2019	11,245	240	789	1,680	N/A
12/31/2018	11,434	353	1,146	2,342	N/A
9/30/2018	11,594	546	1,270	2,201	N/A
6/30/2018	11,719	457	1,098	2,096	N/A
3/31/2018	11,873	717	1,101	2,234	N/A
12/31/2017	11,908	696	1,169	2,065	N/A
9/30/2017	11,937	869	N/A	1,919	N/A
6/30/2017	12,007	661	N/A	2,571	N/A
3/31/2017	11,605	533	N/A	2,420	N/A
12/31/2016	11,077	480	N/A	2,047	N/A
9/30/2016	10,300	257	N/A	2,350	N/A
6/30/2016	9,938	806	N/A	2,124	N/A
3/31/2016	9,749	805	N/A	1,822	N/A
12/31/2015	9,429	848	N/A	2,009	N/A
9/30/2015	9,021	842	N/A	1,483	N/A
6/30/2015	8,410	913	N/A	949	N/A
3/31/2015	7,876	870	N/A	1,014	N/A
12/31/2014	7,720	929	N/A	1,015	N/A
9/30/2014	7,445	920	N/A	1,306	N/A
6/30/2014	7,129	580	N/A	1,280	N/A
3/31/2014	6,993	633	N/A	1,287	N/A
12/31/2013	6,909	624	N/A	1,107	N/A
9/30/2013	6,823	605	N/A	980	N/A
6/30/2013	6,858	658	N/A	1,027	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (16% al año) de VTRS es superior a la tasa de ahorro (2.3%).

Beneficios vs. Mercado: Se prevé que los beneficios (16% al año) de VTRS crezcan más rápidamente que el mercado US (14.7% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de VTRS crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos de VTRS disminuyan en los próximos 3 años (-1.2% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos de VTRS disminuyan en los próximos 3 años (-1.2% al año).

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de VTRS sea baja dentro de 3 años (11%).

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Viatris Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus EPS estimates increase by 11%

Viatris Inc. Reaffirms Revenue Guidance for the Full-Year 2023

Viatris Inc. Reaffirms Revenue Guidance for the Full Year 2022

Price target decreased to US$12.55

Consensus forecasts updated

Recent updates

Inflation Reduction Act: A Bullish Catalyst For Viatris Inc.

Viatris Inc. to Report Q1, 2024 Results on May 09, 2024

Viatris Inc. Announces Launch of First Bioequivalent Generic Version of Copaxone 20 mg/mL Once-Daily in Canada

Viatris Stock: Way Too Undervalued With $1 Billion Buyback Potential

Viatris Inc. Announces the Launch of RYZUMVI (Phentolamine Ophthalmic Solution) 0.75% in the United States

Viatris Stock Is Still Worth Buying

President of Developed Markets recently sold US$3.0m worth of stock

Insud Pharma S.L.U. acquired Women Healthcare business of Viatris Inc. (NasdaqGS:VTRS).

President & Executive Director exercised options and sold US$3.3m worth of stock

Up 25%, I Still Believe 4%-Yielding Viatris Is Up To 60% Undervalued

Fourth quarter dividend of US$0.12 announced

New minor risk - Profit margin trend

Full year 2023 earnings: EPS misses analyst expectations

Viatris Inc. Declares Quarterly Dividend, Payable on March 18, 2024

Viatris Inc. to Report Fiscal Year 2023 Results on Feb 28, 2024

From Euphoria To Reality: Viatris' Tale Of Market Whirlwind

Viatris Announces CFO Changes

Viatris Inc. Appoints Leo Groothuis to Serve on the Compliance and Risk Oversight Committee, Executive Committee and Governance and Sustainability Committee

Upcoming dividend of US$0.12 per share at 5.2% yield

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Viatris Inc. Declares Quarterly Dividend, Payable on December 15, 2023

Viatris Inc., Annual General Meeting, Dec 15, 2023

Now 21% undervalued after recent price drop

Viatris Inc. Announces That Its President, Rajiv Malik, Will Be Retiring as an Executive of the Company Effective April 1, 2024

Viatris Inc. to Report Q3, 2023 Results on Nov 07, 2023

Viatris Inc. and Ocuphire Pharma, Inc. Announce Fda Approval of Ryzumvl™? (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (E.G., Tropicamide) Agents

Viatris Reportedly in Talks to Sell European OTC Assets to CVC

Viatris Inc. Announces U.S. FDA Tentative Approval of Paediatric Formulation of Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC), Once-Daily Treatment for Children Living with HIV

Upcoming dividend of US$0.12 per share at 4.3% yield

Consensus EPS estimates increase by 11%

Viatris Inc. Declares Quarterly Dividend, Payable on September 15, 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Viatris Inc. and Kindeva Drug Delivery L.P. Announces Launch of Breyna (Budesonide and Formoterol Fumarate Dihydrate) Inhalation Aerosol

Viatris Inc. to Report Q2, 2023 Results on Aug 07, 2023

Holzer & Holzer, LLC Announces A Class Action Lawsuit Has Been Filed Against Viatris Inc

Viatris Inc. Announces Board Changes

Johnson Fistel, LLP Files Class Action Lawsuit Against Viatris Inc

Upcoming dividend of US$0.12 per share at 5.1% yield

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Viatris Inc. Reaffirms Revenue Guidance for the Full-Year 2023

CEO & Executive Director exercised options and sold US$972k worth of stock

CEO & Executive Director exercised options and sold US$631k worth of stock

Full year 2022 earnings: EPS exceeds analyst expectations

Biocon Plans to Sell Stake in Biologics Arm to Pare Debt

Viatris Inc. to Report Q4, 2022 Results on Feb 27, 2023

Viatris Inc. (NasdaqGS:VTRS) completed the acquisition of Oyster Point Pharma, Inc. (NasdaqGS:OYST) from a group of shareholders.

Viatris Inc. Announces Changes to its Board

Viatris Inc. Announces Approval of Emissions Reduction Targets by the Science Based Target Initiative

Biocon Biologics Limited completed the acquisition of biosimilars portfolio and related commercial and operational capabilities from Viatris Inc. (NasdaqGS:VTRS).

Upcoming dividend of US$0.12 per share

Viatris Inc. (NasdaqGS:VTRS) entered into a definitive agreement to acquire Oyster Point Pharma, Inc. (NasdaqGS:OYST) for approximately $300 million.

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Viatris Inc. Reaffirms Revenue Guidance for the Full Year 2022

Viatris Inc., Annual General Meeting, Dec 09, 2022

Viatris Inc., Annual General Meeting, Dec 09, 2022

Price target decreased to US$12.55

Viatris Inc. to Report Q3, 2022 Results on Nov 07, 2022

Viatris Reportedly Considers Sale of $3 Billion European OTC Assets

Viatris stock rises amid potential plans for €3B sale of European OTC assets

Take These Broken Wings And Learn To Fly Again Viatris

Viatris: 5% Dividend Yield Is A Threat For Investors

Independent Non-Executive Director recently sold US$100k worth of stock

Viatris: Products, Profitability And Pipeline - The Keys To Success

Upcoming dividend of US$0.12 per share

Consensus forecasts updated

Viatris Inc. Declares Quarterly Dividend, Payable on September 16, 2022

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Viatris declares $0.12 dividend

Viatris: A Spinoff To Own

Viatris extends decline to reach 52-week low